BGB-283 Product

BGB-283 Product. (a) BGB-283 (b) any prodrugs, salts and solvates of BGB-283, (c) any metabolites of BGB-283 (i) whose primary activity is the inhibition of BRAF and which meet the affinity requirements in clause (b) of Section 1.12, and (ii) which are within the claims of the BGB-283 Patent Application, and (d) any dosage form or formulation of the compounds described in clauses (a), (b) and (c)